First-line cetuximab plus cisplatin and fluorouracil vs cisplatin and fluorouracil in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: The randomized, phase III CHANGE-2 trial
Guo, Y.; Luo, Y.; Zhang, Q.; Huang, X.; Li, Z.; Shen, L.; Feng, J.; Sun, Y.; Yang, K.; Ge, M-H.; Zhu, X.; Wang, L.; Liu, Y.; He, X.; Bai, C.; Xue, K.; Zeng, Y.; Cao, Y.; Chen, W.; Lin, T.
Annals of Oncology Official Journal of the European Society for Medical Oncology 29 Suppl. 9: Ix176
2018
ISSN/ISBN: 0923-7534 PMID: 32177936 DOI: 10.1093/annonc/mdy483.005
Accession: 069920093
PDF emailed within 0-6 h: $19.90
Related References
Vermorken, J.B.; Peyrade, F.; Brummendorf, T.H.; Iglesias, L.; Bethe, U.; Hicking, C.; Clement, P.M.; Krauss, J.; Mesia, R.; Remenar, E.; Gauler, T.C.; Keilholz, U.; Delord, J.P.; Schafhausen, P.; Erfan, J. 2014: Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase 1/11 ADVANTAGE trial (phase II part) Annals of Oncology 25(3): 682-688Vermorken, J.B.; Peyrade, F.; Krauss, J.; Mesía, R.; Remenar, E.; Gauler, T.C.; Keilholz, U.; Delord, J.P.; Schafhausen, P.; Erfán, J.; Brümmendorf, T.H.; Iglesias, L.; Bethe, U.; Hicking, C.; Clement, P.M. 2014: Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part) Annals of Oncology: Official Journal of the European Society for Medical Oncology 25(3): 682-688
Vermorken, J.B.; Peyrade, F.; Krauss, J.; Mesía, R.; Remenar, E.; Gauler, T.C.; Keilholz, U.; Delord, J.P.; Schafhausen, P.; Erfán, J.; Brümmendorf, T.H.; Iglesias, L.; Bethe, U.; Hicking, C.; Clement, P.M. 2014: Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/Ii ADVANTAGE trial (phase Ii part) Annals of Oncology: Official Journal of the European Society for Medical Oncology 25(3): 682-688
Guigay, J.ël.; Aupérin, A.; Fayette, J.ér.ôm.; Saada-Bouzid, E.; Lafond, C.éd.; Taberna, M.; Geoffrois, L.; Martin, L.; Capitain, O.; Cupissol, D.; Castanie, H.él.èn.; Vansteene, D.; Schafhausen, P.; Johnson, A.; Even, C.; Sire, C.; Duplomb, S.; Evrard, C.; Delord, J.-P.; Laguerre, B.; Zanetta, S.; Chevassus-Clément, C.éc.; Fraslin, A.ér.; Louat, F.; Sinigaglia, L.; Keilholz, U.; Bourhis, J.; Mesia, R.; Baba-Hamed, N.; Babin, E.; Bera, G.; Betrian-Lagarde, S.; Blot, E.; Bompas, E.; Borel, C.; Bouchekoua, M.; Bozec LE Moal, L.; Bruyas, A.; Calais, G.; Carpiuc, I.; Chapet, S.; Chatellier, T.; Chauffert, B.; Cheli, S.; Clatot, F.; Cojocarasu, O.; Cornelly, A.; Coutte, A.; Dalloz, P.; Darloy, F.; Delhommeau, M.; DE Raucourt, D.; Debel 2021: Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial LANCET. Oncology 22(4): 463-475
Machiels, J.-P.; Kaminsky, M.-C.; Keller, U.; Brümmendorf, T.H.; Goddemeier, T.; Forssmann, U.; Delord, J.-P. 2013: Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck Investigational new Drugs 31(5): 1207-1216
Lorenzen, S.; Schuster, T.; Muller, L.; Rothling, N.; Peschel, C.; Langer, R.; Lordick, F.; Porschen, R.; Albatran, S.E.; Hofheinz, R.; Thusspatience, P.; Moehler, M.; Grabowski, P.; Arnold, D.; Greten, T. 2009: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin- 5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase 11 study of the Arbeitsgemeinschaft lnternistische Onkologie Annals of Oncology 20(10): 1667-1673
Lorenzen, S.; Schuster, T.; Porschen, R.; Al-Batran, S.-E.; Hofheinz, R.; Thuss-Patience, P.; Moehler, M.; Grabowski, P.; Arnold, D.; Greten, T.; Müller, L.; Röthling, N.; Peschel, C.; Langer, R.; Lordick, F. 2009: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase Ii study of the Arbeitsgemeinschaft Internistische Onkologie Annals of Oncology: Official Journal of the European Society for Medical Oncology 20(10): 1667-1673
Klinghammer, K.; Gauler, T.; Dietz, A.; Grünwald, V.; Stöhlmacher, J.; Knipping, S.; Schroeder, M.; Guntinas-Lichius, O.; Frickhofen, N.; Lindeman, H.-W.; Fietkau, R.; Haxel, B.; Große-Thie, C.; Maschmeyer, G.; Zipfel, M.; Martus, P.; Knoedler, M.; Keilholz, U. 2019: Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase Ii randomised trial (AIO/IAG-KHT trial 1108) European Journal of Cancer 122: 53-60
Clavel, M.; Vermorken, J.B.; Cognetti, F.; Cappelaere, P.; de Mulder, P.H.; Schornagel, J.H.; Tueni, E.A.; Verweij, J.; Wildiers, J.; Clerico, M. 1994: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. a phase IIi study of the EORTC Head and Neck Cancer Cooperative Group Annals of Oncology: Official Journal of the European Society for Medical Oncology 5(6): 521-526
Bourhis, J.; Rivera, F.; Mesia, R.; Awada, A.; Geoffrois, L.; Borel, C.; Duck, L.; Bessa, E.; Mueser, M.; Amellal, N. 2003: Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck EJC Suppls 1(5): S34
Bourhis, J.; Rivera, F.; Mesia, R.; Awada, A.; Geoffrois, L.; Borel, C.; Humblet, Y.; Lopez-Pousa, A.; Hitt, R.; Vega Villegas, M.E.; Duck, L.; Rosine, D.; Amellal, N.; Schueler, A.; Harstrick, A. 2006: Phase I/Ii study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24(18): 2866-2872
Vermorken, J.B.; Guigay, J.; Mesia, R.; Trigo, J.M.; Keilholz, U.; Kerber, A.; Bethe, U.; Picard, M.; Brummendorf, T.H. 2011: Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part British Journal of Cancer 104(11): 1691-1696
Vermorken, J.B.; Mesia, R.; Vega-Villegas, M.E.; Remenar, E.; Hitt, R.; Kawecki, A.; Rottey, S.; Zabolotnyy, D.; Erfan, J.; Amellal, N. 2016: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME) Journal of Clinical Oncology 24(18_Suppl): 5537-5537
Mutlu, H.; Salim, D.K.ıv.; Gündüz, Şe.; Eryılmaz, M.K.; Musri, F.Y.çın.; Coşkun, H.Şe. 2017: Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard? Journal of Cancer Research and Therapeutics 13(3): 510-513
Adkins, D.; Ley, J.; Trinkaus, K.; Thorstad, W.; Lewis, J.; Wildes, T.; Siegel, B.A.; Dehdashti, F.; Gay, H.; Mehan, P.; Nussenbaum, B. 2013: A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck Cancer 119(4): 766-773
Cognetti, F.; Clerico, M.; Vermorken, J.; Van Rymenant, M.; Rossi, A.; Kirkpatrick, A.; Dalesic, O.; Clavel, M. 1986: Phase Ii trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck European Journal of Cancer and Clinical Oncology 22(7): 891-892
Cognetti, F.; Dodion, P.; Clerico, M.; Vermorken, J.B.; Van Rijmenant, M.; Clavel, M.; Dalesio, O.; Kirkpatrick, A.; Rossi, A. 1984: Phase ii trial of a combination of low dose cisplatin and bolus 5 fluorouracil in recurrent and metastatic squamous cell carcinoma of the head and neck Cancer Immunology Immunotherapy 18(Suppl): S14
Gebbia, V.; Mantovani, G.; Agostara, B.; Contu, A.; Farris, A.; Colucci, G.; Cognetti, F.; Restivo, G.; Speciale, R.; Ferrero, B. 1995: Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase Ii trial Annals of Oncology: Official Journal of the European Society for Medical Oncology 6(10): 987-991
Paredes, J.; Hong, W.K.; Felder, T.B.; Dimery, I.W.; Choksi, A.J.; Newman, R.A.; Castellanos, A.M.; Robbins, K.T.; McCarthy, K.; Atkinson, N. 1988: Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 6(6): 955-962
Jimeno, A.; Machiels, J.-P.; Wirth, L.; Specenier, P.; Seiwert, T.Y.; Mardjuadi, F.; Wang, X.; Kapp, A.V.; Royer-Joo, S.; Penuel, E.; McCall, B.; Pirzkall, A.; Clement, P.M. 2016: Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck Cancer 122(24): 3803-3811